PURPOSE: The extradomain B of fibronectin (ED-B) is a promising vascular target for selective pharmacodelivery in cancer patients. We analyzed a large series of prostatectomies from patients with prostate cancer, hyperplastic prostate disease, and normal prostates to study extent and tumor-selectivity of ED-B expression. METHODS: Using immunohistology, 68 adenocarcinomas of the prostate or prostate cancer-inflicted lymph nodes, 4 samples of benign prostatic hyperplasia, and 6 normal prostate glands were studied for ED-B expressing newly formed blood vessels. Further, we treated an advanced prostate cancer patient with the anti-ED-B antibody (131)I-L19SIP to study in vivo target accessibility. RESULTS: ED-B-positive blood vessels were found significantly more frequent in prostate cancers as compared with peritumoral prostate tissues or normal prostate glands, independent of tumor differentiation. The ED-B-positive blood vessels' density was 97 (±23), 65 (±9), and 59 (±9)/mm(2) in G3, G2, and G1 prostate cancers, respectively, and 7 (±5)/mm(2) in normal prostate glands. In high-grade (G3) prostate cancers, also the peritumoral tissue showed a higher density of ED-B vessels than normal prostate glands. Similar results were obtained when ED-B-positive vessel density was expressed as a fraction of CD34-positive vessel density. Finally, selective uptake of ED-B-binding (131)I-L19SIP to tumor lesions was found in an advanced prostate cancer patient by whole-body planar scintigraphy. CONCLUSIONS: ED-B-positive blood vessels were found to a large extent in prostate cancer tissues, but only rarely in normal prostates or benign prostatic hyperplasia. Whole-body planar scintigraphy in a prostate cancer patient confirmed selective uptake of (131)I-L19SIP in the prostate cancer tissues, qualifying ED-B as a promising target for selective pharmacodelivery of anticancer agents in prostate cancer.
PURPOSE: The extradomain B of fibronectin (ED-B) is a promising vascular target for selective pharmacodelivery in cancerpatients. We analyzed a large series of prostatectomies from patients with prostate cancer, hyperplastic prostate disease, and normal prostates to study extent and tumor-selectivity of ED-B expression. METHODS: Using immunohistology, 68 adenocarcinomas of the prostate or prostate cancer-inflicted lymph nodes, 4 samples of benign prostatic hyperplasia, and 6 normal prostate glands were studied for ED-B expressing newly formed blood vessels. Further, we treated an advanced prostate cancerpatient with the anti-ED-B antibody (131)I-L19SIP to study in vivo target accessibility. RESULTS:ED-B-positive blood vessels were found significantly more frequent in prostate cancers as compared with peritumoral prostate tissues or normal prostate glands, independent of tumor differentiation. The ED-B-positive blood vessels' density was 97 (±23), 65 (±9), and 59 (±9)/mm(2) in G3, G2, and G1 prostate cancers, respectively, and 7 (±5)/mm(2) in normal prostate glands. In high-grade (G3) prostate cancers, also the peritumoral tissue showed a higher density of ED-B vessels than normal prostate glands. Similar results were obtained when ED-B-positive vessel density was expressed as a fraction of CD34-positive vessel density. Finally, selective uptake of ED-B-binding (131)I-L19SIP to tumor lesions was found in an advanced prostate cancerpatient by whole-body planar scintigraphy. CONCLUSIONS:ED-B-positive blood vessels were found to a large extent in prostate cancer tissues, but only rarely in normal prostates or benign prostatic hyperplasia. Whole-body planar scintigraphy in a prostate cancerpatient confirmed selective uptake of (131)I-L19SIP in the prostate cancer tissues, qualifying ED-B as a promising target for selective pharmacodelivery of anticancer agents in prostate cancer.
Authors: Marcus Czabanka; Güliz Parmaksiz; Simon H Bayerl; Melina Nieminen; Eveline Trachsel; Hans D Menssen; Ralf Erber; Dario Neri; Peter Vajkoczy Journal: Eur J Cancer Date: 2011-03-09 Impact factor: 9.162
Authors: Patrizia Castellani; Laura Borsi; Barbara Carnemolla; Attila Birò; Alessandra Dorcaratto; Giuseppe L Viale; Dario Neri; Luciano Zardi Journal: Am J Pathol Date: 2002-11 Impact factor: 4.307
Authors: G Mariani; A Lasku; A Pau; G Villa; C Motta; G Calcagno; G Z Taddei; P Castellani; K Syrigos; A Dorcaratto; A A Epenetos; L Zardi; G A Viale Journal: Cancer Date: 1997-12-15 Impact factor: 6.860
Authors: Christian M Matter; Pia K Schuler; Patrizia Alessi; Patricia Meier; Romeo Ricci; Dongming Zhang; Cornelia Halin; Patrizia Castellani; Luciano Zardi; Christoph K Hofer; Matteo Montani; Dario Neri; Thomas F Lüscher Journal: Circ Res Date: 2004-11-11 Impact factor: 17.367
Authors: Andrew C Newman; Wayne Chou; Katrina M Welch-Reardon; Ashley H Fong; Stephanie A Popson; Duc Thien Phan; Daniel R Sandoval; Dananh P Nguyen; Paul D Gershon; Christopher C W Hughes Journal: Arterioscler Thromb Vasc Biol Date: 2013-01-03 Impact factor: 8.311
Authors: M W Dewhirst; C Y Tso; R Oliver; C S Gustafson; T W Secomb; J F Gross Journal: Int J Radiat Oncol Biol Phys Date: 1989-07 Impact factor: 7.038